News & Press Releases

Recent News

XPRIZE Rapid Covid Testing competition.

October 09, 2020 8:06 AM Eastern Standard Time
Base Pair Biotechnologies, Inc., The Aptamer Discovery CompanyTM is delighted to announce that the company has been selected as a semi-finalist in the XPRIZE Rapid Covid Testing competition. 219 teams were selected to advance from among approximately 700 total entries. Base Pair will use its proprietary aptamers in a novel electrochemical sensor for rapid testing of saliva samples. As part of the competition, Base Pair will take delivery of inactivated viral antigen samples and apply its test in a blinded fashion. XPRIZE teams that perform the best on this blinded proficiency test will be selected to advance to the next phase of the competition with a chance to win one of five $1M prizes.Read More …

New Grant Award for Discovery of Aptamers to Canine Oncology Biomarkers

Comparative oncology is the study of naturally-occurring cancer in animals to identify treatments that can be applied to humans. Many types of cancer, including several types that are identical to human cancer, are very common in dogs. Clinicians are learning that curing cancer in dogs can frequently result in effective cures for humans. Read more about canine cancer research. Base Pair Biotechnologies has recently been awarded an NIH SBIR Contract entitled, “Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics”. “It is increasingly understood that the canine model is a much higher fidelity representation for studying human cancer than smaller mammals. Using our patented ability to multiplex aptamer selection, Base Pair is in a unique position to rapidly discover affinity reagents to important canine cancer biomarkers. These new reagents should quickly prove useful in the study of cancer in dogs and, ultimately, translation of new therapeutics from preclinical trials to the treatment of human cancers.” – Dr. Bill Jackson, Founder and Chief Scientist, Base Pair Biotechnologies

New Grant Award for Detection of Synthetic Opioids on Surfaces

According to the National Institute on Drug Abuse, overdoses from synthetic opioids, including fentanyl, spiked to almost 30,000 in 2017, up from 5,000 just three years prior. As the availability and use of powerful synthetic opioids escalates, first responders, law enforcement, medical personnel, remediation workers and forensic laboratory personnel are increasingly at risk. Base Pair Biotechnologies has been awarded a grant from the CDC to develop aptamers and lateral flow assays (simple strip tests) for the rapid detection of several synthetical opioids on surfaces. Detection of the presence of powerful opioids can reduce accidental exposure, improve remediation efforts, and confirm required treatment in response to accidental exposure. The grant award titled “Identification and/or Creation of Aptamers with Affinity to Fentanyl, Carfentanil, Acetyl Fentanyl, and Naloxone: Development of Prototype Lateral Flow Assays” is focused on field-based detection of several potent synthetic opioids. Read about other opioid aptamers developed at Base Pair.

Recent News

Rapid Quantification of Two Chemical Nerve Agent Metabolites in Serum using Base Pair Aptamers

Researchers at Vanderbilt University and the CDC have developed a method for quantifying metabolites of two prominent nerve agents, Sarin and Venomous Agent X, using aptamers selected by Base Pair Biotechnologies. Organophosphorus nerve agents are odorless, colorless gases that affect neural communication to muscles and glands. Exposure can cause symptoms ranging from tear production and confusion to vomiting, paralysis, and even death. Low-level exposure is difficult to detect and identification of the nerve agent applied is often an even greater challenge. The team combined a free solution assay, a compensated interferometer, and Base Pair aptamers to selectively detect VX acid (the metabolite of Venomous Agent X) and GB acid (the metabolite of Sarin) at levels below 10 pg/mL in 25% serum. Kammer, M., et al. Rapid quantification of two chemical nerve agent metabolites in serum. Biosensors and Bioelectronics. 2019. https://www.sciencedirect.com/science/article/pii/S0956566319300855  

Base Pair Awarded Grant for Aptamers to Canine Cancer Biomarkers

Base Pair Biotechnologies has recently been awarded an NIH SBIR Contract entitled, “Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics”. “It is increasingly understood that the canine model is a much higher fidelity representation for studying human cancer than smaller mammals. Using our patented ability to multiplex aptamer selection, Base Pair is in a unique position to rapidly discover affinity reagents to important canine cancer biomarkers. These new reagents should quickly prove useful in the study of cancer in dogs and, ultimately, translation of new therapeutics from preclinical trials to the treatment of human cancers.” – Dr. Bill Jackson, Founder and Chief Scientist, Base Pair Biotechnologies

Base Pair Awarded Grant for Detection of Malaria

Base Pair has been awarded a grant from the U.S. Centers for Disease Control (CDC) to develop aptamer-based point-of-care tests for detection of malarial metabolites in urine and saliva.

Base Pair Moves to New Facility

Base Pair facilityBase Pair is excited to announce the opening of our new 5,000+ sq. ft. facility. Still in Pearland, TX, our new facility is just a mile from our original location, convenient to Houston’s biomedical hub and clinical research institutions including MD Anderson, Rice University, and Baylor College of Medicine.

Citrulline Aptamer Now Available from Base Pair

Base Pair has released a new aptamer to L-Citrulline, a small, non-essential amino acid. Based on scientific reports that citrulline promotes muscle protein synthesis and improves blood flow, it has become a popular nutritional supplement. Because citrulline is produced in the small intestine, low citrulline levels are an indication of intestinal failure. Citrulline is metabolized in the kidneys. Elevated levels of citrulline are an indication of kidney failure. Visit the Citrulline Aptamer Page to learn more.

Catalog Aptamers in Multiple Applications

10.19.15 Base Pair is pleased to see researchers using our catalog aptamers beginning to publish their data, recently three articles have been released.  If you have any questions about the use of our aptamers contact us at catalog@basepairbio.com Aptamer-phage reporters for ultrasensitive lateral flow assays Meena Adhikari, Ulrich Strych, Jinsu Kim, Heather Goux, Sagar Dhamane, Mohan-Vivekanandan Poongavanam, Anna E. V. Hagström, Katerina Kourentzi, Jacinta C. Conrad, and Richard C. Willson Anal. Chem., Just Accepted Manuscript DOI: 10.1021/acs.analchem.5b00702 Publication Date (Web): October 12, 2015 Copyright © 2015 American Chemical Society Reversible Aptamer-Au Plasmon Rulers for Secreted Single Molecules Somin Eunice Lee, Qian Chen, Ramray Bhat, Shayne Petkiewicz, Jessica M. Smith, Vivian E. Ferry, Ana Luisa Correia, A. Paul Alivisatos, and Mina J. Bissell Nano Lett., 2015, 15 (7), pp 4564–4570 DOI: 10.1021/acs.nanolett.5b01161 Publication Date (Web): June 3, 2015 Copyright © 2015 American Chemical Society Conformational structure-dependent molecular recognition of two aptamers for tetracycline Sai Wang,a Jiahui Liu,a Yiyang Dong,*a Haijia Sua and Tianwei Tana RSC Adv., 2015,5, 53796-53801 DOI: 10.1039/C5RA08050A Received 01 May 2015, Accepted 10 Jun 2015 First published online 11 Jun 2015

Other News

 

  1. SMART Award donated by Base Pair for Aptamer Development
  2. Base Pair Develops Phosphorylation Site Specific Aptamers for Proteomic Applications
  3. New Article from Base Pair CSO, Aptamer SERS Nanoprobe
  4. Top 12 Hot BioPharma Regions For Growth And Expansion
  5. Another Contract from CDC for Rapid Point-of-Care Tests for Cytomegalovirus
  6. Base Pair Publishes New Article
  7. Protocol for Sandwich Pair Developed
  8. Base Pair Expands Laboratory Space
  9. Sensor100 Newsletter Article
  10. Aptamers That Work(TM) Base Pair Biotechnologies Launches Online Catalog
  11. Dr. Mark Morris Receives Phase I SBIR Contract From The National Cancer Institute
  12. Base Pair CEOCFO Magazine Interview Highlights Aptamer Services
  13. Base Pair Offering $100 Aptamers
  14. Bill Jackson, Ph.D to Present at ‘Aptamers in Medicine and Perspectives’ Workshop
  15. Base Pair Biotechnologies Highlighted in International Innovation Magazine
  16. Base Pair to Present at Lateral Flow Workshop
  17. Pivotal Scientific Ltd and Base Pair Biotechnologies Partner
  18. Poster Selected for Oral Presentation at 45th AACC Oak Ridge Conference: Emerging Technologies for 21st Century Diagnostics
  19. New Application Note – SPR Analysis of Base Pair Aptamers
  20. Base Pair Biotechnologies Signs New Development Agreement for Environmental Test
  21. Aptamer Data Presented at Annual Meeting American Society for Cell Biology, video available
  22. AptaTracker™ for Interactive Online Project Management for Clients During Custom Aptamer Development
  23. Posters Presented at The Southwest Regional Meeting of the American Chemical Society
  24. New Updated Aptamer Market Research Report Available
  25. Biomarker Measurement in Human Serum with Base Pair Aptamers and Vista Therapeutics NanoBiosensor(TM)
  26. Base Pair Researcher Receives $250K Grant for Monitoring of Environmental Toxins in Blood Using Aptamers
  27. $750K Contract from the National Cancer Institute to Develop 75 New Aptamers for Proteomics Research Granted to Base Pair Researcher
  28. Base Pair granted license by the Drug Enforcement Administration (DEA) for research use of controlled substances
  29. Small Molecule Specific Aptamers in a FRET Assay, New Application Note
  30. New Technical Note-Small Molecule Specific Aptamer Binding Analytics Determined by Microscale Thermophoresis
  31. Base Pair Biotechnologies invests in Next Gen Sequencer to improve aptamer services
  32. Base Pair Bio to exhibit at TIDES, May 20-23 in Las Vegas
  33. ForteBio Spring Newsletter Includes Aptamer Characterization Data by Biolayer Interferometry (BLI)
  34. Base Pair Biotechnologies to present binding characterization and aptamer based ELISA developments at AACC
  35. “Ice9 Bio” is now “Base Pair Biotechnologies”!
  36. BasePairBio will be at BioMEMS 2012 March 21-22
  37. Survey Results: Aptamer Adoption and Application
  38. Base Pair Bio researchers receive $1M SBIR grant to further massively parallel aptamer selection
  39. Base Pair Bio receives SBIR Phase I Contract – “Development of Glycosylation-specific Research Aptamers”
  40. Ice9 presents 4 papers at ACS Southwest Regional Meeting
  41. Base Pair Bio partnering with AsamBio to develop ultrasensitive aptamer-ELISAs
  42. ELISA-like assays with aptamers, “ELASA”
  43. Small molecule aptamers

Press Releases

Base Pair Biotechnologies Announces Fast Track SBIR Grant Award from National Institutes of Health

February 21, 2019 8:06 AM Eastern Standard Time PEARLAND, Texas–(PR Newswire)–Base Pair Biotechnologies, Inc., The Aptamer Discovery CompanyTM, today announced the award of an SBIR grant to develop aptamer-based point-of-care tests for opioids to rapidly diagnose neonatal abstinence syndrome. The grant will be used to develop a new platform to detect opioids and their primary metabolites in newborns, enabling rapid treatment.  View the full Press Release … Read more about opioid detection at Base Pair

Base Pair Biotechnologies Completes $3.2 Million Series A-3 Financing Round and Opens New Facility

November 28, 2017   10:40 AM Eastern Standard Time PEARLAND, Texas–(Business Wire)–Base Pair Biotechnologies, Inc., The Aptamer Discovery CompanyTM, today announced the completion of its $3.2 Million Series A-3 financing round and the opening of its new 5,000 square foot laboratory and office facility in Pearland, TX, a Houston suburb.  Toronto-based Eventi Capital Partners Inc. and Base Pair Canada led the round, with participation from earlier investors Houston-based BioTex, Inc. and Ashok Gowda, BioTex’s President & CEO, one of Base Pair’s founders.  Read More …

Base Pair and Nexmos Create DNA Aptamers that Inhibit Vitamin C Oxidation

December 28, 2016   8:00 AM Eastern Standard Time Pearland, Texas, U.S.A. and Seoul, South Korea – (PR Newswire) – Base Pair Biotechnologies, Inc., The Aptamer Discovery Company, and Nexmos, Inc., the Aptamer Application R&D Company, announce the creation of a new class of DNA-aptamer based oxidation inhibitors.  These molecules stabilize vitamin C, enabling development of new cosmetics, nutraceuticals, beverages and therapeutic agents with longer shelf life and potentially greater efficacy.  Nexmos plans to launch the first product containing these molecules in the second half of 2017, as a component of an antioxidant beverage formulation, in collaboration with a major health beverage company.  Read More …